BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 17912361)

  • 1. Design and pre-clinical evaluation of a universal HIV-1 vaccine.
    Létourneau S; Im EJ; Mashishi T; Brereton C; Bridgeman A; Yang H; Dorrell L; Dong T; Korber B; McMichael AJ; Hanke T
    PLoS One; 2007 Oct; 2(10):e984. PubMed ID: 17912361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
    Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
    J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).
    Mothe B; Manzardo C; Sanchez-Bernabeu A; Coll P; Morón-López S; Puertas MC; Rosas-Umbert M; Cobarsi P; Escrig R; Perez-Alvarez N; Ruiz I; Rovira C; Meulbroek M; Crook A; Borthwick N; Wee EG; Yang H; Miró JM; Dorrell L; Clotet B; Martinez-Picado J; Brander C; Hanke T
    EClinicalMedicine; 2019; 11():65-80. PubMed ID: 31312806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
    Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical development of BCG.HIVA
    Mahant A; Saubi N; Eto Y; Guitart N; Gatell JM; Hanke T; Joseph J
    Hum Vaccin Immunother; 2017 Aug; 13(8):1798-1810. PubMed ID: 28426273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
    Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
    PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
    Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.
    Bråve A; Boberg A; Gudmundsdotter L; Rollman E; Hallermalm K; Ljungberg K; Blomberg P; Stout R; Paulie S; Sandström E; Biberfeld G; Earl P; Moss B; Cox JH; Wahren B
    Mol Ther; 2007 Sep; 15(9):1724-33. PubMed ID: 17579577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a DNA-MVA/HIVA vaccine for Kenya.
    Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
    Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons.
    Burgers WA; Chege GK; Müller TL; van Harmelen JH; Khoury G; Shephard EG; Gray CM; Williamson C; Williamson AL
    J Gen Virol; 2009 Feb; 90(Pt 2):468-480. PubMed ID: 19141458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short conserved sequences of HIV-1 are highly immunogenic and shift immunodominance.
    Yang OO; Ali A; Kasahara N; Faure-Kumar E; Bae JY; Picker LJ; Park H
    J Virol; 2015 Jan; 89(2):1195-204. PubMed ID: 25378501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
    Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
    J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa.
    Nkolola JP; Wee EG; Im EJ; Jewell CP; Chen N; Xu XN; McMichael AJ; Hanke T
    Gene Ther; 2004 Jul; 11(13):1068-80. PubMed ID: 15164090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.
    Amara RR; Sharma S; Patel M; Smith JM; Chennareddi L; Herndon JG; Robinson HL
    Virology; 2005 Mar; 334(1):124-33. PubMed ID: 15749128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
    Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
    J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
    Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
    J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gag and env conserved element CE DNA vaccines elicit broad cytotoxic T cell responses targeting subdominant epitopes of HIV and SIV Able to recognize virus-infected cells in macaques.
    Hu X; Lu Z; Valentin A; Rosati M; Broderick KE; Sardesai NY; Marx PA; Mullins JI; Pavlakis GN; Felber BK
    Hum Vaccin Immunother; 2018; 14(9):2163-2177. PubMed ID: 29939820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
    Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
    J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
    Hanke T; Barnfield C; Wee EG; Ågren L; Samuel RV; Larke N; Liljeström P
    J Gen Virol; 2003 Feb; 84(Pt 2):361-368. PubMed ID: 12560568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.